Reiseimpfungen – Hinweise und Empfehlungen

Zusammenfassung

Der Ständige Ausschuss Reisemedizin (StAR) der Deutschen Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit (DTG) gibt jährlich Empfehlungen zu Reiseimpfungen heraus. Diese Empfehlungen, erstellt von unabhängigen Experten, umfassen länderspezifische und risikobasierte Impfstrategien sowie verpflichtende Impfungen für internationale Reisen. Sie dienen als Entscheidungshilfe für medizinisches Fachpersonal und berücksichtigen Erkenntnisse u. a. der WHO, des ECDC und nationaler Gesundheitsbehörden.

Abstract

The Standing Committee for Travel Medicine (StAR) of the German Society for Tropical Medicine, Travel Medicine, and Global Health (DTG) provides annual recommendations on travel vaccinations. These practice guidelines, developed by independent experts, cover country-specific and risk-based vaccination strategies, including mandatory immunizations for international travel. The recommendations serve as a decision-making tool for healthcare professionals, incorporating insights from WHO, ECDC, national health authorities and others.

Schlüsselwörter

Reisemedizin - Reiseimpfungen - Reisende mit Immunsuppression - Reisen mit Kindern - Schwangere

Key words

travel medicine - travel vaccines - immunocompromised travelers - paediatric travelers - pregnant travelers

Publication History

Article published online:
09 April 2025

• Literatur

• 1 Ständige Impfkommission und Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e. V. unter besonderer Mitarbeit von Kling K. Külper-Schiek W. et al. Empfehlungen der Ständigen Impfkommission (STIKO) und der Deutschen Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e. V. (DTG) zu Reiseimpfungen. Epid Bull 2024; 14: 1-206
• 2 Steffen R, Chen LH, Leggat PA. Travel vaccines-priorities determined by incidence and impact. J Travel Med 2023; 30: taad085
• 3 Connor BA, Dawood R, Riddle MS. et al. Cholera in travellers: a systematic review. J Travel Med 2019; 26: taz085
• 4 World Health Organization. Statement of the fortieth meeting of the Polio IHR Emergency Committee. 3 December 2024. www.who.int/news/item/03–12–2024-statement-of-the-fortieth-meeting-of-the-polio-ihr-emergency-committee
• 5 Robert Koch-Institut. Hinweis auf Schluckimpfstoff-abgeleitete Polioviren in Abwasserproben an mehreren Orten in Deutschland. Epid Bull 2024; 48: 21-22
• 6 Ministry of Health. Health Requirements and Recommendations for Travelers to Saudi Arabia for Umrah and Visit – 1446 H. 2025 www.moh.gov.sa/en/HealthAwareness/Pilgrims_Health/Documents/Health-Regulations-Umrah-EN.pdf
• 7 DTG. Weltwärts-Untersuchungen. www.dtg.org/index.php/listetropenmedizinischer-institutionen/weltwaerts-informationen-fueraerzte.html
• 8 Robert Koch-Institut. Durchführung der COVID-19-Impfung (Stand 26.9.2024). www.rki.de/SharedDocs/FAQs/DE/Impfen/COVID-19/FAQ_Liste_Durchfuehrung_Impfung.html
• 9 Ständige Impfkommission. Empfehlungen der Ständigen Impfkommission (STIKO) beim Robert Koch-Institut 2025. Epid Bull 2025; 4: 1-75
• 10 Harris A. Hepatitis B. In: CDC. CDC Yellow Book 2024. Oxford University Press; 2023
• 11 Heyward WL, Kyle M, Blumenau J. et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age. Vaccine 2013; 31: 5300-5305
• 12 Hirve S, Newman LP, Paget J. et al. Influenza Seasonality in the Tropics and Subtropics – When to Vaccinate?. PLoS One 2016; 11: e0153003
• 13 Schlaberg J, Buda S, Dürrwald R. et al. Beschluss für die Empfehlung der STIKO zum Wechsel von quadrivalenten zu trivalenten Influenza-Impfstoffen. Epid Bull 2024; 31: 9-11
• 14 Laws JH, Baumann U, Bogdan C. et al. Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2020; 63: 588-644
• 15 Bundeszentrale für gesundheitliche Aufklärung. Masernschutz.de. www.masernschutz.de
• 16 Gershman M, Staples JE. Yellow Fever. In: CDC. CDC Yellow Book 2024. Oxford University Press; 2023
• 17 Monath TP, Vasconcelos PF. Yellow fever. J Clin Virol 2015; 64: 160-173
• 18 NaTHNaC. Yellow fever vaccine recommendation maps. https://nathnacyfzone.org.uk/factsheet/60/yellow-fever-vaccine-recommendation-maps
• 19 Kling K, Bogdan C, Burchard G. et al. STIKO-Empfehlung zur Gelbfieber-Auffrischimpfung vor Reisen in Endemiegebiete und für exponiertes Laborpersonal. Epid Bull 2022; 32: 3-35
• 20 Kling K, Domingo C, Bogdan C. et al. Duration of Protection After Vaccination Against Yellow Fever: A Systematic Review and Meta-Analysis. Clin Infect Dis 2022; 75: 2266-2274
• 21 Gnanadurai R, Campo-Matos I, Kanagarajah S. et al. National review of reported Yellow fever vaccine incidents in the UK. Travel Med Infect Dis 2022; 102289
• 22 Staples JE, Monath TP, Gershman MD. et al. Yellow Fever Vaccines. In: Orenstein W, Offit P, Edwards KM. et al. Plotkin’s Vaccines. 7. Philadelphia: Elsevier; 2017: 1181-1265
• 23 StAR. Aufklärungsmerkblatt, Fragebogen und Einverständniserklärung vor Impfung gegen Gelbfieber. www.dtg.org/images/Startseite-Download-Box/Gelbfieber-Aufklaerung_DTG_STAR_0223.pdf
• 24 Bwaka A, Bita A, Lingani C. et al. Status of the rollout of the Meningococcal Serogroup A Conjugate Vaccine in African Meningitis Belt Countries in 2018. J Infect Dis 2019; 220 (4) S140-S147
• 25 Ruiz Garcia Y, Abitbol V, Pellegrini M. et al. A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine. Infect Dis Ther 2022; 11: 639-655
• 26 Peterson ME, Li Y, Bita A. et al. Meningococcal serogroups and surveillance: a systematic review and survey. J Glob Health 2019; 9: 010409
• 27 Cramer JP, Wilder-Smith A. Meningococcal disease in travelers: update on vaccine options. Curr Opin Infect Dis 2012; 25: 507-517
• 28 Steffen R. The risk of meningococcal disease in travelers and current recommendations for prevention. J Travel Med 2010; 17: 9-17
• 29 Peterson J, Drazan D, Moughan B. et al. Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose. Vaccine 2025; 43 (1) 126469
• 30 Nolan T, Bhusal C, Hoberman A. et al. Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults who had Previously Received a Meningococcal ACWY Vaccine: Phase 3, Randomized, Controlled Clinical Study. Clin Infect Dis 2024;
• 31 Nolan T, Bhusal C, Beran J. et al. Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial. Lancet Infect Dis 2024;
• 32 GSK. Penmenvy. GSK’s 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY. 15 February 2025. Accessed March 07, 2025 at: https://www.gsk.com/en-gb/media/press-releases/penmenvy-gsk-s-5-in-1-meningococcal-vaccine-approved-by-us-fda-to-help-protect-against-menabcwy/
• 33 GSK. Prescribing Information Penmenvy. Revised: 2/2025 Accessed March 07, 2025 at: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Penmenvy/pdf/PENMENVY.PDF
• 34 World Health Organization. Meningococcal vaccines: WHO position paper on the use of multivalent meningococcal conjugate vaccines in countries of the African meningitis belt. Weekly Epidemiological Record 12.01.2024
• 35 World Health Organization. Vaccination schedule for Meningococcal disease. 2024 https://immunizationdata.who.int/pages/schedule-by-disease/meningococcal.html
• 36 Piechotta V, Koch J, Bogdan C. et al. Empfehlung zur Standardimpfung von Säuglingen gegen Meningokokken der Serogruppe B und die dazugehörige wissenschaftliche Begründung. Epid Bull 2024; 3: 3-32
• 37 Böttcher S, Kreibich J, Wilton T. et al. Detection of circulating vaccine-derived poliovirus type 2 (cVDPV2) in wastewater samples: a wake-up call, Finland, Germany, Poland, Spain, the United Kingdom, 2024. Euro Surveill 2025; 30
• 38 Robert Koch-Institut. Update zu cVDPV2-Nachweisen im Abwasser. Epid Bull 2025; 5: 10-11
• 39 World Health Organization. International Travel and Health – 18 November 2022 (Revised on 3 January 2023).Country List – Country vaccination requirements and WHO recommendations for vaccination against yellow fever, poliomyelitis, and malaria prophylaxis in international travellers. 2022 ed. Geneva: WHO; 2022: 46
• 40 Steffen R, Acar J, Walker E. et al. Cholera: assessing the risk to travellers and identifying methods of protection. Travel Med Infect Dis 2003; 1: 80-88
• 41 Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch für 2022. Berlin: 2024
• 42 World Health Organization. Dengue and severe Dengue. Accessed April 12, 2024 at: www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue
• 43 Aktuelle Statistik meldepflichtiger Infektionskrankheiten. Epid Bull 2025; 1: 12
• 44 Lachmann R, Frank C. Starker Anstieg der Denguefieber-Meldefallzahlen in den ersten Monaten 2024. Epid Bull 2024; 20/21: 3-8
• 45 Halstead SB. Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age. Vaccine 2017; 35: 6355-6358
• 46 Tricou V, Low JG, Oh HM. et al. Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: A phase 2, double-blind, randomised, controlled trial. Vaccine 2020; 38: 1513-1519
• 47 Kling K, Külper-Schiek W, Schmidt-Chanasit J. et al. STIKO-Empfehlung und wissenschaftliche Begründung der STIKO zur Impfung gegen Dengue mit dem Impfstoff Qdenga. Epid Bull 2023; 48: 3-43
• 48 Van Heuverswyn J, Hallmaier-Wacker LK, Beauté J. et al. et al. Spatiotemporal spread of tick-borne encephalitis in the EU/EEA, 2012 to 2020. Euro Surveill 2023; 28: 2200543
• 49 Erber W, Khan F, Zavadska D. et al. Effectiveness of TBE vaccination in southern Germany and Latvia. Vaccine 2022; 40: 819-825
• 50 Nygren TM, Pilic A, Böhmer MM. et al. Tick-borne encephalitis vaccine effectiveness and barriers to vaccination in Germany. Sci Rep 2022; 12: 11706
• 51 Steffen R, Erber W, Schmitt HJ. Can the booster interval for the tick-borne encephalitis (TBE) vaccine ‘FSME-IMMUN’ be prolonged? – A systematic review. Ticks Tick Borne Dis 2021; 12: 101779
• 52 Schmidt SM. Impfen: Was tun bei bestehenden Allergien?. Dtsch Arztebl 2018; 115: 48
• 53 Wiedermann-Schmidt U, Maurer W. [Adjuvants and additives in vaccines--medical relevance]. Wien Klin Wochenschr 2005; 117: 510-519
• 54 Balogun O, Brown A, Angelo DO KM. et al. Acute hepatitis a in international Travelers: A GeoSentinel analysis, 2008–2020. J Travel Med 2022; taac013
• 55 Ministerio de Sanidad. Aumento de casos de Hepatitis A en España. 2024 Accessed December 20, 2024 at: www.sanidad.gob.es/areas/alertasEmergenciasSanitarias/alertasActuales/hepatitis/docs/20241220_ERR_HepatitisA.pdf
• 56 Srivastava KS, Jeswani V, Pal N. et al. Japanese Encephalitis Virus: An Update on the Potential Antivirals and Vaccines. Vaccines (Basel) 2023; 11: 742
• 57 Kling K, Harder T, Younger Z. et al. Vaccination against Japanese encephalitis with IC51: systematic review on immunogenicity, duration of protection and safety. J Travel Med 2020; 27: taaa016
• 58 AG Reiseimpfungen der Ständigen Impfkommission (STIKO): Kling K. Bogdan C, Burchard G. et al. Wissenschaftliche Begründung für die Empfehlung zur Impfung gegen Japanische Enzephalitis bei Reisen in Endemiegebiete und für Laborpersonal. Epid Bull 2020; 18: 5-27
• 59 European Food Safety Authority (EFSA), European Centre for Disease Prevention and Control (ECDC). The European Union One Health 2022 Zoonoses Report. EFSA J 2023; 21: e8442
• 60 European Food Safety Authority (EFSA), European Centre for Disease Prevention and Control (ECDC). The European Union One Health 2022 Zoonoses Report. EFSA J 2024; 22: e9106
• 61 Henry RE, Blanton JD, Angelo KM. et al. A country classification system to inform rabies prevention guidelines and regulations. J Travel Med 2022; 29: taac046
• 62 Gautret P, Angelo KM, Asgeirsson H. et al. Rabies post-exposure prophylaxis started during or after travel: A GeoSentinel analysis. PLoS Negl Trop Dis 2018; 12: e0006951
• 63 World Health Organization. Rabies Vaccines: WHO position paper – April 2018. Weekly Epidemiological Record 2018; 93: 201-220
• 64 Auswärtiges Amt. Vorgehen bei Kontakt mit tollwutverdächtigen Tieren im Ausland. 02/25. https://www.auswaertiges-amt.de/blob/251026/63ede1f7da0361ace59b36be85951e9b/tollwutkontakt-data.pdf
• 65 GBD 2017 Typhoid and Paratyphoid Collaborators. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis 2019; 19: 369-381
• 66 Hancuh M, Walldorf J, Minta AA. et al. Typhoid Fever Surveillance, Incidence Estimates, and Progress Toward Typhoid Conjugate Vaccine Introduction – Worldwide, 2018–2022. MMWR Morb Mortal Wkly Rep 2023; 72: 171-176
• 67 Falkenhorst G, Frank C, Faber M. et al. Zur Situation bei wichtigen Infektionskrankheiten – Importierte Infektionskrankheiten 2023. Epid Bull 2024; 45: 3-21
• 68 Yousafzai MT, Qamnar FN, Shakoor S. et al. Ceftriaxone-resistant Salmonella Typhi Outbreak in Hyderabad City of Sindh, Pakistan: High Time for the Introduction of Typhoid Conjugate Vaccine. Clin Infect Dis 2019; 68 (1) S16-S21
• 69 Posen HJ, Wong W, Farrar DS. et al. Travel-associated extensively drug-resistant typhoid fever: a case series to inform management in non-endemic regions. J Travel Med 2023; 30: taac086
• 70 Carey ME, McCann NS, Gibani MM. Typhoid fever control in the 21st century: where are we now?. Curr Opin Infect Dis 2022; 35: 424-430
• 71 Meiring JE, Shakya M, Khanam F. et al. Burden of enteric fever at three urban sites in Africa and Asia: a multicentre population-based study. Lancet Glob Health 2021; 9: e1688-e1696
• 72 Faucher JF, Binder R, Missinou MA. et al. Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines. Clin Infect Dis 2002; 35: 1147-1154
• 73 UK Health Security Agency. Typhoid: the green book, chapter 33. Accessed April 03, 2020 at: www.gov.uk/government/publications/typhoid-the-green-book-chapter-33
• 74 Patel PD, Liang Y, Meiring JE. et al. Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children. Lancet 2024; 403: 459-468
• 75 Bartholomeeusen K, Daniel M, LaBeaud DA. et al. Chikungunya fever. Nat Rev Dis Primers 2023; 9: 17
• 76 European Centre for Disease Prevention and Control. Local transmission of chikungunya virus in mainland EU/EEA, 2007–present. Accessed August 13, 2024 at: www.ecdc.europa.eu/en/infectious-disease-topics/chikungunya-virus-disease/surveillance-threats-and-outbreaks/local
• 77 Mayer AB, C PH. Grobusch MP. et al. Chikungunya in returning travellers from Bali – A GeoSentinel case series. Travel Med Infect Dis 2023; 52: 102543
• 78 Simon F, Caumes E, Jelinek T. et al. Chikungunya: risks for travellers. J Travel Med 2023; 30: taad008
• 79 Schneider M, Narciso-Abraham M, Hadl S. et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2023; 401: 2138-2147
• 80 McMahon R, Toepfer S, Sattler N. et al. Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study. Lancet Infect Dis 2024; 24: 1383-1392
• 81 Bennett SR, McCarty JM, Ramanathan R. et al. Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial. Lancet Infect Dis 2022; 22: 1343-1355
• 82 Richardson JS, Anderson DM, Mendy J. et al. Chikungunya Virus VLP Vaccine: Phase 3 Trial in Adolescents and Adults. Accessed October 15, 2024 at: www.medrxiv.org/content/10.1101/2024.10.11.24315179v1
• 83 Tindale LC, Richardson JS, Anderson DM. et al. Chikungunya Virus VLP Vaccine: Phase 3 Trial in Adults ≥ 65 Years of Age. 10/2024 www.researchgate.net/publication/384860047_Chikungunya_Virus_VLP_Vaccine_Phase_3_Trial_in_Adults_65_Years_of_Age
• 84 Ehl S, Bogdan C, Niehues T. et al. Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (II) Impfen bei 1. Primären Immundefekterkrankungen und 2. HIV-Infektion. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2018; 61: 1034-1051
• 85 Niehues T, Bogdan C, Hecht J. et al. Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (I) Grundlagenpapier. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2017; 60: 674-684
• 86 Wagner N, Assmus F, Arendt G. et al. Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (IV) Impfen bei Autoimmunkrankheiten, bei anderen chronisch-entzündlichen Erkrankungen und unter immunmodulatorischer Therapie. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2019; 62: 494-515
• 87 Chang L, Lim BC, Flaherty GT. et al. Travel vaccination recommendations and infection risk in HIV-positive travellers. J Travel Med 2019; 26: taz034
• 88 Rolfes L, Pfeuffer S, Skuljec J. et al. Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine. Cells 2023; 12: 1243
• 89 Allen V, Longley N. Infections in immunosuppressed travellers with autoimmune inflammatory diseases-a narrative review and advice for clinical practice. Rheumatology (Oxford) 2021; 60: 3969-3976
• 90 Rosdahl A, Herzog C, Frösner G. et al. An extra priming dose of hepatitis A vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression – A prospective, open-label, multi-center study. Travel Med Infect Dis 2018; 21: 43-50
• 91 Eperon G, Bühler S, Enriquez N. et al. [The immunosuppressed traveler: vaccination guidelines]. Rev Med Suisse 2018; 14: 922-933
• 92 Huber F, Ehrensperger B, Hatz C. et al. Safety of live vaccines on immunosuppressive or immunomodulatory therapy – a retrospective study in three Swiss Travel Clinics. J Travel Med 2018; 25
• 93 Bühler S, Jaeger VK, Eperon G. et al. Safety and immunogenicity of a primary yellow fever vaccination under low-dose methotrexate therapy – a prospective multi-centre pilot study1. J Travel Med 2020; 27: taaa126
• 94 Wroński J, Jaszcyk B, Roszkowski L. et al. Humoral and cellular immunogenicity of COVID-19 booster dose vaccination in inflammatory arthritis patients. Front Immunol 2022; 13: 1033804
• 95 Yap RXL, Lai YW, Wei C. et al. Impact of Immunomodulatory Therapy on COVID-19 Vaccine Response in Patients with Autoimmune Inflammatory Rheumatic Diseases. Vaccines (Basel) 2024; 12: 274
• 96 Winkelmann A, Loebermann M, Barnett M. et al. Vaccination and immunotherapies in neuroimmunological diseases. Nat Rev Neurol 2022; 18: 289-306
• 97 Gabay C, Bel M, Combescure C. et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 2011; 63: 1486-1496
• 98 Chat VS, Ellebrecht CT, Kingston P. et al. Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2024; 90: 1170-1181
• 99 Emi Aikawa N, Andrade Balbi V, Borba EF. et al. Yellow fever vaccination in Brazil: Short-term safety and immunogenicity in juvenile autoimmune rheumatic diseases. Vaccine X 2021; 10: 100131
• 100 Dipchand AI, Seifert-Hansen M. Early experience with varicella vaccination in pediatric heart transplant recipients. J Heart Lung Transplant 2022; 41: 1023-1026